Ly-294002

Ly-294002

SCHEMBL5078472

Cl.O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Ly-294002. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD known ✓ O00329 1/20 0.97
PDE5A known ✓ O76074 1/20 0.97
HTR2A known ✓ P28223 1/20 0.97
HTR2C known ✓ P28335 1/20 0.97
HTR2B known ✓ P41595 1/20 0.97
PIK3CA known ✓ P42336 1/20 0.97
PDE3B known ✓ Q13370 1/20 0.97
PDE3A known ✓ Q14432 1/20 0.97
ALDH1A1 P00352 3/20 1.00
KDM4E B2RXH2 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
GMNN O75496 1/20 1.00
LMNA P02545 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
PRKDC P78527 18/20 0.97
BRD4 O60885 2/20 0.97
BRD2 P25440 2/20 0.97
BRD3 Q15059 2/20 0.97
PDE2A O00408 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ly-294002 SCHEMBL29424167 0.99 PRKDC (1.00) ALDH1A1KDM4ESMN1; SMN2GMNNLMNA
Ly-294002 SCHEMBL94377 0.99 PRKDC (1.00) ALDH1A1KDM4ESMN1; SMN2GMNNLMNA
SCHEMBL13496867 0.97 PRKDC (0.97) ALDH1A1KDM4ESMN1; SMN2GMNNLMNA
SCHEMBL31061056 0.94 PRKDC (1.00) ALDH1A1KDM4ESMN1; SMN2GMNNLMNA
SCHEMBL14041172 0.93 PRKDC (1.00) ALDH1A1KDM4ESMN1; SMN2GMNNLMNA
SCHEMBL5261685 0.89 PRKDC (0.81) ALDH1A1KDM4ESMN1; SMN2GMNNLMNA
SCHEMBL5260468 0.89 PRKDC (0.81) ALDH1A1KDM4ESMN1; SMN2GMNNLMNA
SCHEMBL4423159 0.89 PRKDC (0.81) ALDH1A1KDM4ESMN1; SMN2GMNNLMNA
SCHEMBL31060584 0.88 PRKDC (1.00) ALDH1A1KDM4ESMN1; SMN2GMNNLMNA
SCHEMBL13700043 0.88 PRKDC (0.80) ALDH1A1KDM4ESMN1; SMN2GMNNLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4416268-A1 METHODS FOR PRODUCING CARTILAGE AND BONES Murdoch Children's Research Institute (AU) 2024-08-21 EP claimed
CN-118355110-A Method for producing cartilage and bone 默多克儿童研究所 2024-07-16 CN claimed
CN-118291390-A Construction method of zebra fish bone loss model 华芯微鱼(苏州)生物科技有限公司 2024-07-05 CN claimed
WO-2023060322-A1 METHODS FOR PRODUCING CARTILAGE AND BONES MURDOCH CHILDREN'S RESEARCH INSTITUTE (AU) 2023-04-20 WO claimed
US-20140024663-A1 ATB(0,+) AMINO ACID TRANSPORTER AS A DRUG TARGET FOR TREATMENT OF ESTROGEN RECEPTOR-POSITIVE BREAST CANCER GEORGIA HEALTH SCIENCES UNIVERSITY RES INST INC (US) 2014-01-23 US claimed
EP-2943564-B1 SL327 FOR USE IN SKIN REGENERATION INT STEM CELL CORPORATION (US) 2026-03-25 EP disclosed
EP-4680255-A1 METHODS FOR PRODUCING STABLE HUMAN CHONDROCTYES AND THEIR USE FOR PROMOTING CARTILLAGE GROWTH AND REPAIR The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2026-01-21 EP disclosed
EP-4677064-A1 METHODS AND COMPOSITIONS FOR IN VITRO HAEMATOPOIESIS AND LYMPHOPOIESIS Murdoch Children's Research Institute (AU) 2026-01-14 EP disclosed
WO-2024254483-A9 GENERATING POPULATIONS OF HUMAN BLOOD AND BLOOD VESSEL PROGENITORS FROM PLURIPOTENT STEM CELLS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-11-06 WO disclosed
US-20250270507-A1 METHODS FOR PRODUCING CARTILAGE AND BONES MURDOCH CHILDREN'S RESEARCH INSTITUTE OF THE ROYAL CHILDREN'S HOSPITAL (AU) 2025-08-28 US disclosed
US-20250154467-A1 CREATION OF VASCULARIZED BIOLOGICAL STRUCTURES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2025-05-15 US disclosed
WO-2024254483-A2 GENERATING POPULATIONS OF HUMAN BLOOD AND BLOOD VESSEL PROGENITORS FROM PLURIPOTENT STEM CELLS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-12-12 WO disclosed
US-20140308743-A1 METHOD FOR CULTURING STEM CELL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-10-16 US disclosed
EP-2774983-A1 METHOD FOR CULTURING STEM CELL Riken (JP) 2014-09-10 EP disclosed
WO-2014039994-A2 TARGETING CHEMOTHERAPY AGENT RESISTANCE IN CANCER CORDON-CARDO CARLOS (US) 2014-03-13 WO disclosed
US-20140024663-A1 ATB(0,+) AMINO ACID TRANSPORTER AS A DRUG TARGET FOR TREATMENT OF ESTROGEN RECEPTOR-POSITIVE BREAST CANCER GEORGIA HEALTH SCIENCES UNIVERSITY RES INST INC (US) 2014-01-23 US disclosed
WO-2013119518-A1 SMALL MOLECULES FOR ISLET EXPANSION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-08-15 WO disclosed
US-20080139457-A1 Therapeutic compositions comprising chorionic gonadotropins and HMG CoA reductase inhibitors VIRGINIA COMMONWEALTH UNIVERSITY (US) 2008-06-12 US disclosed
WO-2007035395-A9 THERAPEUTIC COMPOSITIONS COMPRISING CHORIONIC GONADOTROPINS AND HMG COA REDUCTASE INHIBITORS UNIV VIRGINIA COMMONWEALTH (US) 2007-06-14 WO disclosed
WO-2007035395-A2 THERAPEUTIC COMPOSITIONS COMPRISING CHORIONIC GONADOTROPINS AND HMG COA REDUCTASE INHIBITORS VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION (US) 2007-03-29 WO disclosed